The Role of Galectins in the Non-invasive Diagnosis of Endometriosis

Launched by SEMMELWEIS UNIVERSITY · May 20, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the role of a specific protein called Galectin-9 (Gal-9) in diagnosing endometriosis, a common condition that affects many women and can lead to chronic pain and infertility. Currently, diagnosing endometriosis often requires a surgical procedure called laparoscopy, which can be invasive and carries risks. The researchers believe that measuring Gal-9 levels in the blood could provide a safer, non-invasive way to diagnose this condition. Previous studies have shown that women with endometriosis have higher levels of Gal-9 compared to healthy individuals, which suggests it could be a promising marker for diagnosis.

To be eligible for this trial, participants must be women aged between 18 and 45 who have been diagnosed with endometriosis through a biopsy. Women who have received hormone therapy recently are not eligible to participate. Those who join the study can expect to provide blood samples for testing Gal-9 levels. The hope is that this research can lead to a more straightforward and less invasive way to diagnose endometriosis, allowing for earlier and more effective treatment options. If you're considering participating, this trial could be an important step in improving care for women with endometriosis.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Histologically proved endometriosis
• Exclusion Criteria:
• • Previous or current hormone therapy